RNA interference mediating small RNA molecules

Details for Australian Patent Application No. 2002235744 (hide)

Owner Europaisches Laboratorium fur Molekularbiologie (EMBL) MaxPlanck-Gesellschaft Zur Forderung Der Wissenschaften e.V.

Inventors Tuschl, Thomas; Luhrmann, Reinhard; Wilm, Mattias; Lendeckel, Winfried; Elbashir, Sayda

Agent Davies Collison Cave

Pub. Number AU-B-2002235744

PCT Pub. Number WO02/44321

Priority 00126325.0 01.12.00 EP; 60/279,661 30.03.01 US

Filing date 29 November 2001

Wipo publication date 11 June 2002

Acceptance publication date 19 April 2007

International Classifications

A01H 5/00 (2006.01) Products

A01K 67/027 (2006.01) Rearing or breeding animals, not otherwise provided for - New breeds of vertebrates

A61K 31/7105 (2006.01) - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 48/00 (2006.01) Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases

A61P 31/12 (2006.01) Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

C12N 15/11 (2006.01) Mutation or genetic engineering - DNA or RNA fragments

C12P 21/02 (2006.01) Preparation of peptides or proteins - having a known sequence of two or more amino acids, e.g. glutathione

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/15 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Medicinal preparations

G01N 33/50 (2006.01) Investigating or analysing materials by specific methods not covered by groups - Chemical analysis of biological material, e.g. blood, urine

G01N 33/68 (2006.01) Investigating or analysing materials by specific methods not covered by groups - involving proteins, peptides or amino acids

Event Publications

29 July 2004 Amendment Made

  The nature of the amendment is: Add the coinventor Luhrmann, Reinhard

8 December 2005 Amendment Made

  The nature of the amendment is: Delete priority details PCT/US01/10188 30 Mar 2001 US 2002248763 AK Steel Properties, Inc. The nature of the amendment is: Amend the name of the applicant from AK Properties, Inc. to AK Steel Properties, Inc. 2002250552 AK Steel Properties, Inc. The nature of the amendment is: Amend the name of the applicant from AK Properties, Inc. to AK Steel Properties, Inc. 2002252617 AK Steel Properties, Inc. The nature of the amendment is: Amend the name of the applicant from AK Propert

19 April 2007 Application Accepted

  Published as AU-B-2002235744

28 June 2007 Corrigenda

  Applications Accepted - Name Index Under the names Europaisches Laboratorium fur Molekularbiologie (EMBL) and Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften e.V., Application No. 2002235744, under INID (72), correct the co-inventor name to read Wilm, Matthias

16 August 2007 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002235745

2002235743-Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect